Intrapleural tPA and DNase for Loculated Pleural Effusions
Combination tissue plasminogen activator (tPA) and dornase alfa (DNase/Pulmozyme) should be administered intrapleurally when initial chest tube drainage has ceased and leaves a residual pleural collection in patients with pleural infection or complicated parapneumonic effusion. 1
When to Use
The 2023 British Thoracic Society guidelines provide clear criteria for initiating intrapleural fibrinolytic therapy:
- After failed initial drainage: Use combination therapy when chest tube output has stopped but imaging shows persistent loculated fluid 1
- Not as first-line treatment: Initial management should be small-bore chest tube (≤14F) drainage with appropriate antibiotics 1
- Do NOT use single-agent therapy: Neither tPA alone nor DNase alone should be used—only the combination is recommended 1
Clinical Context for Pleural Infection
Consider intrapleural therapy when:
- Pleural fluid pH <7.2 with clinical features supporting complicated parapneumonic effusion (ongoing fever, high fluid volume, low glucose ≤4.0 mmol/L, septations on ultrasound, pleural enhancement on CT) 1
- Chest tube drainage has plateaued despite adequate positioning
- Patient is not a surgical candidate or surgery is being deferred
How to Administer
Standard Dosing Protocol
The evidence-based regimen is:
- tPA 10 mg twice daily PLUS DNase 5 mg twice daily for 3 days (total of 6 doses each) 1
This is based on the landmark MIST-2 trial data incorporated into current guidelines.
Alternative Lower-Dose Regimen
- tPA 5 mg twice daily PLUS DNase 5 mg twice daily for 3 days may be equally effective based on retrospective data and can be used when necessary 1
- Consider reduced tPA doses in patients at higher bleeding risk (e.g., those on therapeutic anticoagulation that cannot be temporarily stopped) 1
Administration Technique
- Instill medications through the chest tube
- Clamp the chest tube for 1 hour after administration
- Resume drainage to suction or water seal
- Repeat dosing every 12 hours
Recent real-world data suggests concurrent administration (tPA and DNase given immediately after one another) may be as effective as sequential administration with 1-2 hour separation, with similar safety profiles 2. However, formal compatibility and stability data are lacking.
Important Caveats and Safety Considerations
Bleeding Risk
- Major bleeding is rare (0.8% in multicenter cohorts) 3
- Obtain informed consent discussing bleeding risk 1
- Consider dose reduction in high-risk patients rather than avoiding therapy entirely
- One bleeding event was reported across multiple studies reviewed
Pain Management
- Peri-procedural pain requiring additional analgesia occurs in approximately 40-57% of patients 3, 4
- Proactively plan analgesic strategies before initiating therapy
- Pain does not appear to differ significantly between concurrent and sequential administration 2
Expected Outcomes
Real-world effectiveness data shows:
- Treatment success (avoiding surgery) ranges from 71-100% depending on patient selection 3, 4, 5
- Median increase in chest tube drainage of approximately 487-538 mL after therapy 3, 5
- Radiographic improvement in 84-90% of patients 5
When Therapy Fails
If after the standard 6-dose regimen (3 days) there is:
- Persistent fever
- Persistently elevated inflammatory markers
- Residual loculations on imaging
Extended therapy beyond 6 doses may be considered in carefully selected high-risk patients who are not surgical candidates, though this is based on case reports rather than guideline recommendations 6. The alternative is proceeding to video-assisted thoracoscopic surgery (VATS), which is preferred over thoracotomy for surgical management 1.
What NOT to Do
- Do not use streptokinase—it is ineffective and increases complications 1
- Do not use single-agent tPA or DNase—neither is effective alone 1
- Do not use for malignant pleural effusions—indwelling pleural catheters are preferred for loculated malignant effusions 7
- Do not use Pulmozyme via inhalation for pleural disease—the FDA-approved indication is for cystic fibrosis via nebulization 8; intrapleural use is off-label
Context: Malignant vs Infectious Effusions
The guidelines distinguish clearly between etiologies:
- For pleural infection/empyema: tPA + DNase is appropriate 1
- For malignant pleural effusions with loculations: indwelling pleural catheters are preferred over chemical pleurodesis 7
This distinction is critical—do not confuse management strategies between these two fundamentally different disease processes.